[{"address1": "9704 Medical Center Drive", "city": "Rockville", "state": "MD", "zip": "20850", "country": "United States", "phone": "301 251 5172", "fax": "301 251 5321", "website": "https://www.macrogenics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 \u00d7 CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B \u00d7 CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.", "fullTimeEmployees": 339, "auditRisk": 3, "boardRisk": 3, "compensationRisk": 6, "shareHolderRightsRisk": 7, "overallRisk": 5, "governanceEpochDate": 1717200000, "maxAge": 86400, "priceHint": 4, "previousClose": 4.12, "open": 4.12, "dayLow": 4.04, "dayHigh": 4.38, "regularMarketPreviousClose": 4.12, "regularMarketOpen": 4.12, "regularMarketDayLow": 4.04, "regularMarketDayHigh": 4.38, "beta": 2.003, "forwardPE": -2.1317074, "volume": 6290150, "regularMarketVolume": 6290150, "averageVolume": 2534653, "averageVolume10days": 1777200, "averageDailyVolume10Day": 1777200, "bid": 4.31, "ask": 4.37, "bidSize": 200, "askSize": 200, "marketCap": 273708384, "fiftyTwoWeekLow": 3.14, "fiftyTwoWeekHigh": 21.88, "priceToSalesTrailing12Months": 6.3128996, "fiftyDayAverage": 9.2111, "twoHundredDayAverage": 10.182825, "currency": "USD", "enterpriseValue": 123483224, "profitMargins": -0.53599, "floatShares": 51562996, "sharesOutstanding": 62633500, "sharesShort": 8888623, "sharesShortPriorMonth": 8599115, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.1419, "heldPercentInsiders": 0.02646, "heldPercentInstitutions": 1.1321499, "shortRatio": 2.44, "shortPercentOfFloat": 0.1742, "impliedSharesOutstanding": 62633500, "bookValue": 1.697, "priceToBook": 2.5751324, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -23239000, "trailingEps": -0.38, "forwardEps": -2.05, "pegRatio": 0.01, "enterpriseToRevenue": 2.848, "enterpriseToEbitda": -0.705, "52WeekChange": -0.1922366, "SandP52WeekChange": 0.26238096, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "MGNX", "underlyingSymbol": "MGNX", "shortName": "MacroGenics, Inc.", "longName": "MacroGenics, Inc.", "firstTradeDateEpochUtc": 1381411800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "322da638-92af-3f5e-9fb0-7915224804a7", "messageBoardId": "finmb_600911", "gmtOffSetMilliseconds": -14400000, "currentPrice": 4.37, "targetHighPrice": 18.0, "targetLowPrice": 4.0, "targetMeanPrice": 10.8, "targetMedianPrice": 8.5, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 10, "totalCash": 184236992, "totalCashPerShare": 2.942, "ebitda": -175064992, "totalDebt": 34012000, "quickRatio": 3.433, "currentRatio": 3.633, "totalRevenue": 43357000, "debtToEquity": 32.04, "revenuePerShare": 0.699, "returnOnAssets": -0.38774, "returnOnEquity": -0.21575001, "freeCashflow": -51757876, "operatingCashflow": -111015000, "revenueGrowth": -0.628, "operatingMargins": -5.9040003, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]